For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.

31st Aug 10

Agreement for European Marketing of Bronchitol

Pharmaxis today announced a strategic marketing and sales service agreement for the commercialisation of Bronchitol for cystic fibrosis in Europe.


Read full media release - pdf
8th Jul 10

Update on Pharmaxis CEO

The Chairman of the Pharmaxis Ltd Board, Mr Denis Hanley advises that Pharmaxis Chief Executive Officer, Dr Alan Robertson, continues to recover after undergoing a medical procedure three weeks ago.


Read full media release - pdf
22nd Jun 10

Pharmaxis Announces Results for Second Phase III Trial of Bronchitol in Cystic Fibrosis

Pharmaxis is pleased to announce top line results from the second large-scale global Phase III trial (CF302) of Bronchitol® (mannitol inhalation powder) in patients with cystic fibrosis (CF).

The results support the early and sustained improvement in lung function in cystic fibrosis patients seen in the first phase III study (CF301) and Pharmaxis will now move forward to meet the U.S. Food & Drug Administration (FDA) later this year to discuss a New Drug Application (NDA) for Bronchitol.


Read full media release - pdf